The U.S. District Court for the District of Rhode Island Sept. 30 denied motions from AbbVie and Novartis seeking a preliminary injunction against the state’s law protecting 340B pricing for contract pharmacy arrangements. The two companies were also denied a preliminary injunction in Maine last week.

Judge John McConnell Jr. delivered the order from the bench. “The drug manufacturers have tested other similar state statutes through lawsuits and requests for injunctive relief based on the same or similar legal claims,” he said. “This court has reviewed the statutes, case law, the parties’ briefs, as well as amicus briefs. Based on its own reasoning and that of its sister courts, the court agrees that the plaintiffs are not likely to succeed on the merits of their claim.” 

The AHA filed amicus briefs (AbbVie, Novartis) in these cases opposing the drug companies’ motions and has opposed similar challenges by drug companies in multiple states.

Related News Articles

Headline
The Department of Health and Human Services Feb. 13 issued a request for information on a new 340B rebate model program. The RFI said HHS’ Health Resources and…
Headline
The House Energy and Commerce Subcommittee on Health Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the…
Headline
The 5th U.S. Circuit Court of Appeals Feb. 9 affirmed a district court ruling upholding Louisiana’s 340B contract pharmacy law. The state law prohibits…
Headline
The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart…
Headline
A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and…
Blog
Public
Many Americans may be unaware that the services they rely on every day through their local hospital are supported by a program called the 340B Drug Pricing…